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Purpose: Many viruses have evolved mechanisms to evade detection by the host immune
system. The herpes simplex gene ICP47 encodes a protein that binds to the host anti-
gen-processing transporter, inhibiting the formation of major histocompatibility com-
plex class I (MHC-I) antigens in infected cells. MHC-I antigen expression is also impor-
tant in acute allograft rejection. This study was designed to quantitate the effect of ade-
noviral-mediated gene transfer of ICP47 on MHC-I cell surface expression of human
vascular cells. We hypothesized that the transduction of vascular cells with a replication-
incompetent adenoviral vector that was expressing ICP47 (AdICP47) would inhibit
constitutive and inducible MHC-I expression and thereby reduce the rate of cytolysis of
ICP47-transduced vascular cells by sensitized cytotoxic T lymphocytes (CTL).
Methods: A replication-incompetent adenoviral vector, AdICP47, was created to express
ICP47 driven by the cytomegalovirus immediate early promoter. Cultured human vas-
cular endothelial and smooth muscle cells and human dermal fibroblasts were trans-
duced with either AdICP47 or the control empty vector AddlE1. Cell surface constitu-
tive and γ-interferon–induced MHC-I expression were quantitated by flow cytometry. A
standard 4-hour chromium release cytotoxicity assay was used to determine the percent
cytolysis of transduced and nontransduced endothelial cells by sensitized CTL. Finally,
to quantitate the specificity of the effect of ICP47 on MHC-I expression, adhesion mol-
ecule expression was quantitated in both transduced and nontransduced cells.
Results: Constitutive MHC-I expression in AdICP47-transduced endothelial cells was
inhibited by a mean of 84% ± 5% (SEM) in five experiments. After 48 hours of exposure
to γ-interferon, AdICP47-transduced cells exhibited a mean of 66% ± 8% lower MHC-I
expression than nontransduced cells. Similar inhibition in MHC-I expression was
achieved in AdICP47-transduced vascular smooth muscle cells and dermal fibroblasts.
Percent cytolysis of AdICP47-transduced endothelial cells by CTL was reduced by 72%.
Finally, the specificity of the effect of transduction of ICP47 on vascular cell MHC-I
expression was confirmed by a lack of significant change in either constitutive or tumor
necrosis factor–induced vascular cell adhesion molecule/intercellular adhesion molecule
expression.
Conclusion: Transduction of vascular cells with AdICP47 strongly inhibits both consti-
tutive and inducible MHC-I expression in human vascular cells. AdICP47-transduced
cells exhibited a substantial reduction in cytolysis by CTL. Thus AdICP47 transduction
holds promise as a technique to characterize the role of MHC-I expression in acute vas-
cular allograft rejection in vivo and as a potential therapeutic intervention. (J Vasc Surg
2000;31:558-66.)
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The major histocompatibility complex class I
(MHC-I) protein is a ubiquitous molecule that is
expressed on all nucleated cells. MHC-I antigen pre-
sentation initiates the detection and clearance of for-
eign cells of virally infected host cells by CD8+ T
lymphocytes. In nature, several viruses have evolved
mechanisms to evade host immune detection and
destruction by interfering with the normal produc-
tion or expression of MHC-I antigens.
Under normal circumstances, peptides destined
to be present on MHC-I molecules are generated
by ubiquitin-dependent proteosomes in the
cytosol. A transmembrane protein known as the
transporter of antigen-processing protein (TAP)
mediates transport of the cytosolic peptides into
the lumen of the endoplasmic reticulum. Herpes
simplex virus (HSV) expresses an immediate-early
protein, ICP47, a 9-kDa protein that binds to the
peptide-binding site of the TAP. Once ICP47 is
bound to the TAP, translocation of cytosolic pep-
tides into the lumen of the endoplasmic reticulum
is inhibited.1-3 The formation of stable cell-surface
MHC-I complexes requires the trimolecular associ-
ation of class I heavy chain, β2 microglobulin, and
the peptide within the lumen of the endoplasmic
reticulum. Without the peptide, the class I heavy
chain and the β2 microglobulin remain misfolded
and unstable and thus are unable to be expressed
on the cell surface.
With the use of this strategy, the HSV is able to
inhibit host cell-surface MHC-I expression in a vari-
ety of cells. Within hours of infection by HSV,
fibroblasts become resistant to cytolysis by anti-
HSV cytotoxic T lymphocytes (CTL).4,5 When
CD8+ T cells recognize foreign MHC-I antigens,
an inflammatory cellular infiltration is stimulated.
Cytokines such as interleukin-1 are secreted. Also,
the expression of thrombomodulin and intercellular
adhesion molecule-1 (ICAM-1) is stimulated. Thus
downregulation of MHC-I antigens by ICP47
could potentially reduce allograft rejection mediat-
ed by CD8+ T cells.
Coronary and peripheral arterial bypass grafts
typically are performed with autologous saphenous
veins. Synthetic small diameter grafts have inferior
patency. Venous allografts have been explored as an
alternative when suitable autogenous conduit is
unavailable. Unfortunately, the patency rates of both
fresh and cryopreserved allografts have been inferior
to those of autologous conduit. Rejection as evi-
denced by an inflammatory cellular infiltrate has been
observed.6-12 Immunosuppression, such as with
cyclosporine, reportedly improved patency.6,10,12-14
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This study was designed to quantitate the effect
that adenoviral-mediated gene transfer ICP47 into
human endothelial cells has on cell surface MHC-I
expression to explore the potential of the ICP47
gene to modulate vascular allograft rejection. We
hypothesized that transduction of vascular cells with
a replication-incompetent adenoviral vector that
expresses ICP47 (AdICP47) would inhibit constitu-
tive and inducible MHC-I expression and thereby
reduce the rate of cytolysis of ICP47-transduced vas-
cular cells by sensitized CTL. Gamma-interferon (γ-
IFN) was used to induce MHC-I expression because
its mechanism of increasing the transcription rate of
class I antigens in cultured human endothelial cells is
well documented.15 These studies are the necessary
first step to the establishment of the feasibility of ade-
noviral-mediated gene transfer of ICP47 with the
aim of inhibiting acute vascular allograft rejection.
MATERIAL AND METHODS
Cell lines and medium. Human iliac artery
endothelial cells were derived from discarded aortoil-
iac segments of organ donors by dispase (Boerhinger
Mannheim, Indianapolis, Ind) digestion at 40
IU/mL. Verification of endothelial identity was con-
firmed by morphologic feature (monolayer growth
pattern, polygonal shape, growth pattern exhibiting
contact inhibition), dil Ac-LDL-uptake (Biomedical
Technologies, Stoughton, Mass), and staining with
monoclonal antibody to vonWillebrand factor. En-
dothelial cells were propagated in complete medium
composed of M199, 20% heat-inactivated fetal bovine
serum (Hy Clone, Logan, Utah), 15 U/mL heparin
(Sigma, St Louis, Mo), 25 µg/mL endothelial cell
growth supplement (Collaborative Biomedical,
Bedford, Mass), 100 U/mL penicillin, 100 µg/mL
streptomycin, and 5 mmol/L L-glutamine (Gibco,
Germantown, Md). Endothelial cells were grown on
1% gelatin-coated tissue culture–treated polystyrene
flasks. Human aortic smooth muscle cells and
human dermal fibroblasts were obtained through
American Type Culture Collection (Rockville, Md)
and propagated in minimum essential medium with
10% heat-inactivated fetal bovine serum, 100 U/mL
penicillin, 100 µg/mL streptomycin, and 5 mmol/L
L-glutamine.
Viral vectors. A replication-incompetent ade-
noviral vector containing the ICP47 gene was con-
structed as described previously.16 Briefly, the herpes
simplex 1 gene ICP47 driven by the human
cytomegalovirus (HCMV) immediate-early promoter
was cloned into the E1-deleted region of an E1, E3-
deleted adenoviral backbone and called AdICP47-1.
(From here forward, the vector described as
AdICP47-1 will be called AdICP47.) AdhpAP is
similar to AdICP47 except that the expression cas-
sette is a reporter gene that encodes human placen-
tal alkaline phosphatase. This gene was selected as a
reporter to quantitate transduction efficiency,
because the protein is heat stable above 65°C and
can be distinguished from endogenous alkaline
phosphatase by heat inactivation. AddlE1, the con-
trol empty vector, is essentially identical to AdICP47
and AdhpAP, except without the expression cassette.
All adenovirus was amplified in the permissive
human embryonic kidney 293 line (Microbix,
Ontario, Canada). After viral purification with
cesium chloride, viral stocks were dialyzed against
3% sucrose and stored at –80°C.
Transductions. Vascular cells were grown in T-
25 flasks and were transduced at 80% confluence at
a multiplicity of infection (MOI) of 100 plaque-
forming units (pfu)/cell in a total volume of 1.5 mL
of complete medium. After a 4-hour transduction
period, excess virus was aspirated. The cells were
rinsed in buffered saline solution and fed either
complete medium or complete medium supple-
mented with 200 IU/mL human recombinant γ-
IFN (Gibco). After 48 hours, cell surface MHC-I
expression was quantified by flow cytometry.
Flow cytometry and antibodies. All flow
cytometry was carried out on a FACSCALIBUR
(Becton-Dickinson, San Jose, Calif). Cells were
stained in 96-well V-bottom microtiter plates with
approximately 1 × 105 cells/well in three replicates.
Fluorescein isothiocyanate–conjugated anti–HLA-
A, -B, -C antibody, phycoerythrin-conjugated
anti–HLA-DR, -DP, -DQ, and appropriate isotypic
controls were purchased through PharMingen (San
Diego, Calif). Anti-CD3, -CD4, -CD8, and -CD56
were purchased through Becton Dickinson (San
Jose, Calif). A random sample of 10,000 events was
collected per replicate. Monoclonal antibody against
vonWillebrand factor was obtained from Dako
(Carpenteria, Calif).
Lymphocyte sensitization. Lymphocytes
(responder cells) of haplotype HLA-A 11 and 24
and HLA-B 60 and 62 were sensitized to endothe-
lial cells (stimulator cells) of haplotype HLA-A 1 and
24 and HLA-B 44 and 61 by the following method.
Lymphocytes were derived from whole blood by
Ficoll gradient with Histopaque 1077 (Sigma).
Endothelial cells were grown to confluence on 1%
gelatin-coated wells of a 24-well plate (Becton
Dickinson). Lymphocytes suspended in Yssel’s
medium with 1% human AB serum (Gemini,
Calabasas, Calif) were added to the endothelial cells
at an effector-to-target ratio of 5:1. After 4 days of
sensitization, human recombinant interleukin-2
(Sigma) was added at a concentration of 40 U/mL.
After 7 days of sensitization, the lymphocytes were
harvested and resuspended at a ratio of 4 × 105
cells/mL in Yssel’s medium.17,18 The sensitized
lymphocytes require restimulation with feeder cells
for normal growth. The feeder cells were comprised
of irradiated (4000 rad) human peripheral blood
lymphocytes at a concentration of 2 × 106 cells/mL
and irradiated (5000 rad) JY cells at a concentration
of 2 × 105 cells/mL.19 Four days after the addition
of feeder cells, 40 U/mL of human recombinant
interleukin-2 was added. Sensitized lymphocytes
were used as effectors in a standard 4-hour chromi-
um release cytotoxicity assay 7 days after the addi-
tion of the stimulator cells.
Cytotoxicity assay. Endothelial cells that had
been transduced with either the control empty
vector (AddlE1) or AdICP47 were harvested from
their flasks with trypsin and counted. Each cell
type was labeled with 100 µCi sodium chromate
per million cells for a 2-hour labeling period. Cells
were rinsed twice and recounted. Then 2500 tar-
gets were added to each well of a V-bottom 96-
well plate to which effector cells were added at
effector-to-target cell ratios of 100:1, 50:1, 25:1,
or 12.5:1. To obtain minimum counts (from spon-
taneous release), culture medium was added to tar-
get cells. To obtain maximum counts, Triton-X 1%
in water was added to target cells. Target and
effector cells were incubated at 37°C for 4 hours,
after which time the microtiter plate was spun at
1000 rpm, and 100 µL supernatant was removed
and added to 100 µL scintillation cocktail (Wallac,
Gaithersburg, Md).
Immunoblotting. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis was carried out
on a 15% gel. After transfer onto a 0.2 µm nitro-
cellulose membrane and overnight blocking with a
5% dry milk solution in Tris buffered saline solu-
tion-Tween, primary antibody against ICP47 was
added and followed by a biotin-linked goat anti-
rabbit secondary antibody (Jackson Immunolabs,
West Grove, Pa). Color was developed with an
Enhanced Chemiluminescence (Amersham, En-
gland) and autoradiography.
Adhesion molecule expression. Human iliac
artery endothelial cells were grown on 1% gelatin-
coated T-25 flasks to quantitate the effect of ICP47
on adhesion molecule expression. At 80% conflu-
ence, the cells were transduced with either the con-
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trol empty vector, AddlE1, or AdICP47 at MOI of
100 pfu/cell. After a 4-hour transduction period,
excess virus was aspirated. The cells were rinsed in
buffered saline solution and fed either complete
medium or complete medium supplement with
100 U/mL human recombinant tumor necrosis
factor-α (TNF-α; Sigma). After 48 hours, ICAM-1
and vascular cell adhesion molecule-1 (VCAM)
expression was quantified by flow cytometry. Cells
were stained in 96-well V-bottom microtiter plates
with approximately 1 × 105 cells/well in three
replicates. Fluorescein isothiocyanate-conjugated
(mouse IgG1, K) and phycoerythrin-conjugated
(mouse IgG1) were purchased through
PharMingen. A random sample of 10,000 events
was collected per replicate.
Statistical analysis. The Friedman’s Test was
used, comparing the mean percent change in cell
fluorescence and the percent cytotoxicity to assess
the significance between the multiple groups. The
Wilcoxon Signed Rank Test was used to find the sig-
nificant differences.
RESULTS
Transduction efficiency. To determine whether
adenoviral vectors could infect and transduce human
endothelial cells, we used AdhpAP. Infection of
human endothelial cells with the reporter transgene
AdhpAP led to a nearly 100% transduction rate
determined by histochemical staining (results not
shown).
Inhibition of cell-surface MHC-I on
AdICP47-transduced human endothelial cells. In
five experiments, the transduction of human
endothelial cells with an AdICP47 vector at an MOI
of 100 pfu/cell resulted in a mean inhibition of con-
stitutive MHC-I expression by 84% ± 4.8% (mean ±
SEM), with a range of 74% to 96% reduction (P <
.05; Fig 1). No significant difference in MHC-I
expression was observed between the nontransduced
and AddlE1-transduced endothelial cells. After the
cells were exposed to 200 IU/mL of γ-IFN for 48
hours, both the nontransduced and AddlE1-trans-
duced endothelial cells had an increase in MHC-I by
250% and 229% of constitutive, respectively. The
Fig 1. Transduction of human endothelial cells with AdICP47 resulted in a mean inhibition
of constitutive MHC-I by 84% (range, 74%-96%). On induction with γ-IFN, nontransduced
and AddlE1-transduced cells increased MHC-I expression by 250% and 229% of constitutive
expression, respectively. AdICP47-transduced cells exhibited a mean reduction in MHC-I
expression 66% lower than did constitutive nontransduced endothelial cells. Data are expressed
as the mean ± SEM of five experiments that were performed in triplicate. *P < .05 compared
with constitutive nontransduced endothelial cells by the Wilcoxon signed rank test.
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MHC-I expression of AdICP47-transduced endothe-
lial cells after γ-IFN remained 66% ± 8%, below that
of constitutive nontransduced endothelial cells. Thus
near complete inhibition of both constitutive and γ-
IFN induced MHC-I expression was achieved by
transduction with AdICP47.
Inhibition of cell-surface MHC-I expression
on AdICP47-transduced human vascular smooth
muscle cells. In five experiments, the transduction
of human vascular smooth muscle cells with
AdICP47 resulted in a 67% ± 2.7% lower MHC-I
expression than did the nontransduced cells (P <
.05). No significant difference existed between the
level of MHC-I on nontransduced and AddlE1-
transduced smooth muscle cells. After exposure of
the cells to γ-IFN for 48 hours, the MHC-I expres-
sion on nontransduced and AddlE1-transduced
smooth muscle cells increased by 328% and 267% of
constitutive, respectively. AdICP47-transduced
smooth muscle cells exhibited an 89% ± 0.9% lower
MHC-I expression than did the nontransduced
smooth muscle cells exposed to γ-IFN (Fig 2). Thus
delivery of ICP47 into vascular smooth muscle cells
also results in a substantial reduction in both consti-
tutive and γ-IFN–induced MHC-I expression.
Inhibition of cell-surface MHC-I expression
on AdICP47-transduced human dermal fibro-
blasts. In five experiments, the transduction of
human dermal fibroblasts with AdICP47 resulted
in a mean inhibition of constitutive MHC-I
expression by 80% ± 2.9% (range, 70%-87%; P <
.05). No significant difference existed between the
level of MHC-I expression on the nontransduced
and AddlE1-transduced fibroblasts. After exposure
to 200 IU/mL of γ-IFN for 48 hours, both the
nontransduced and AddlE1-transduced dermal
fibroblasts increased MHC-I expression by 222%
and 185% of constitutive, respectively. AdICP47-
transduced dermal fibroblasts exhibited an 88% ±
1.6% lower MHC-I expression than did the non-
transduced dermal fibroblasts exposed to γ-IFN
(Fig 3).
Fig 2. Transduction of human aortic vascular smooth muscle cells with AdICP47 resulted in
a mean inhibition of constitutive MHC-I expression by 67% (range, 60%-74%). On induction
with γ-IFN, nontransduced and AddlE1-transduced cells increased MHC-I expression by
328% and 267% of constitutive expression, respectively. AdICP47-transduced cells exhibited a
mean inhibition in cell-surface MHC-I expression 51% lower than did constitutive nontrans-
duced cells. Data are expressed as the mean ± SEM of five experiments that were each per-
formed in triplicate. *P < .05 compared with constitutive nontransduced vascular smooth mus-
cle cells by the Wilcoxon signed rank test.
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AdICP47-transduced endothelial cells are
protected from cytolysis by CTL. With the use of
a standard 4-hour chromium release cytotoxicity
assay, the cytotoxicity of a polyclonal group of sen-
sitized lymphocytes was tested against nontrans-
duced, AddlE1-transduced, and AdICP47-trans-
duced endothelial cells. At all effector-to-target
ratios tested in seven experiments, percent cytolysis
of AdICP47-transduced endothelial cells was
46.5% to 71.15% lower than that of either non-
transduced or AddlE1-transduced cells (P < .02;
Fig 4). No significant difference in cytolysis was
found between the nontransduced and AddlE1-
transduced endothelial cells.
The ICP47 protein is identified in AdICP47-
transduced endothelial cells. With the use of stan-
dard sodium dodecyl sulfate-polyacrylamide gel
electrophoresis immunoblotting, the presence of the
ICP47 protein was verified in AdICP47-transduced
endothelial cells with appropriate negative bands in
the nontransduced and AddlE1-transduced groups
(Fig 5).
Effect of AdICP47 transduction on
VCAM/ICAM expression. To determine the
specificity of the effect of the transduction of ICP47
on vascular cell MHC-I expression, we sought to
compare constitutive and TNF-induced VCAM/
ICAM expression of transduced and nontransduced
cells. There were no differences in constitutive or
TNF-induced VCAM expression between AddlE1 or
AdICP47 transduced endothelial cells (Table I). The
constitutive ICAM expression was also not significant-
ly changed in the AdICP47-transduced endothelial
cells from the AddlE1-transduced cells. Finally, the
TNF-induced ICAM expression was not significantly
different in the AdICP47-transduced groups com-
pared with the nontransduced groups.
DISCUSSION
This study shows that the transduction of human
endothelial cells, vascular smooth muscle cells, and
dermal fibroblasts with AdICP47 results in potent
inhibition of the expression of MHC-I under both
constitutive and γ-IFN–induced conditions. Fur-
Fig 3. Transduction of human dermal fibroblasts with AdICP47 results in a mean inhibition of
constitutive MHC-I expression by 80% (range, 70%-87%). On induction with γ-IFN, nontrans-
duced and AddlE1-transduced dermal fibroblasts increased MHC-I expression by 222% and
185% of constitutive expression, respectively. AdICP47-transduced fibroblasts exhibited a mean
inhibition of MHC-I expression 59% lower than did constitutive nontransduced cells. Data are
expressed as mean ± SEM of five experiments that were each performed in triplicate. *P < .05
compared with constitutive nontransduced fibroblasts by the Wilcoxon signed rank test.
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thermore, this ICP47-induced reduction in MHC-I
expression was biologically significant. The ICP47-
transduced cells were protected against cytolysis by
sensitized T lymphocytes in a standard cytotoxicity
assay. This ICP47-induced inhibition of MHC-I
expression appeared to be specific. Although it is
well known that adenoviral transduction of endothe-
lial cells causes a cellular activation as seen with
VCAM/ICAM,20 the ICP47 transgene did not sig-
nificantly change the expression of such mediators.
In light of the findings of this study, several ques-
tions must be addressed. First, is the magnitude of
reduction in MHC-I sufficient to produce an effect
in vivo? Unfortunately, it is not yet known how
many MHC-I molecules are needed to initiate a
response by CTL. However as few as 500 MHC-II
molecules are sufficient to stimulate a proliferative
response to allogeneic cells. Therefore the dramatic
Fig 5. Western blotting reveals positive bands in the 9-kDa range in the lanes corresponding
to lysate from AdICP47-transduced endothelial cells. No signal is present in lanes containing
lysate from nontransduced or AddlE1-transduced endothelial cells.
Fig 4. At each effector-to-target cell ratio, percent cytolysis of AdICP47-transduced endothe-
lial cells is between 47% and 71% lower than that of either nontransduced or AddlE1-trans-
duced cells. *P < .02. Percent cytolysis between nontransduced and AddlE1-transduced
endothelial cells was not significant.
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reduction in surface class I that we observed, cou-
pled with relatively low endogenous levels of class I
molecules in endothelial cells, suggests that ICP47
could reduce CD8+ T-cell responses to vascular allo-
grafts. The results of the experiments that involved
cytotoxicity of sensitized T cells indicate that recog-
nition by CD8+ T cells is reduced. Still, there is some
MHC-I remaining on the cells, probably because of
TAP-independent mechanisms. One method to rec-
tify this problem is to express the HCMV gene,
US2, in cells. US2 is one of the unique short regions
on the HCMV that encodes a glycoprotein that
causes the degradation of MHC-I heavy chains.21
Downregulation of MHC-I may be best achieved by
combining the effects of ICP47 and US2.
A second important issue is whether this degree
of downregulation of MHC-I leads to the induction
of tolerance. This question remains largely unan-
swered and is related to a third issue of whether this
reduction in MHC-I molecules will result in an
increased response of natural killer (NK) cells. It is
certainly possible that the NK-cell response will
become an important means of eliminating allogenic
cells that express ICP47. However, not all MHC-I is
completely inhibited by the vector. Recently, a 
second strategy, one of decoy, used by the HCMV 
to evade host NK cell recognition and destruction
has been discovered.22 The HCMV UL-18 gene
encodes a protein product homologous to the
MHC-I heavy chain. This molecule is recognized by
NK cells and serves as a decoy that inhibits NK cell
lysis of the infected cell. If our in vivo system indi-
cates substantial NK cell response, we would choose
to use a hybrid vector containing the UL-18, US2,
and ICP47.
The downregulation of MHC-I prolonging allo-
graft survival was demonstrated by Efrat et al.23 In
this study, the E3 region of the adenovirus was
introduced into pancreatic islet cells of transgenic
mice. The E3 region contains the gp 19K gene,
which downregulates MHC-I expression by binding
specifically to class I antigens as they are being trans-
ported to the cell surface.24 These MHC-I–depleted
pancreatic islet cells were transplanted into allogenic
mice. Prolonged allograft survival was noted with-
out any other type of additional immunosuppres-
sant. Use of the gp19K gene can, however, be prob-
lematic because it binds to different haplotypes with
differing affinities. The ICP47 gene product binds
to TAP. In some haplotypes, that will not interfere
with the level of MHC-I cell-surface expression.
However, studies with ICP47 have been slowed
because ICP47 does not effectively block the murine
TAP2 so that porcine or primate models are required
to test its efficacy in vivo.
We chose to reduce MHC-I on endothelial cells
because this strategy has been used effectively in
nature by the adenovirus, HSV, and HCMV to evade
host immune responses. Our preliminary studies
with these three genes US11, gp19K, and ICP47
revealed most pronounced reduction in MHC-I with
the ICP47 gene (data not shown). Very few studies
have been undertaken to test the efficacy of these
gene products on endothelial cells or other compo-
nents of the vascular wall. An adenoviral vector was
chosen to introduce ICP47 into these cells for sever-
al reasons. Adenoviruses are known for their high
transduction efficiency. The effect of expressed aden-
oviral proteins and immune destruction of the vector
might be abrogated by the immune-suppressant
effect of the ICP47 gene. Although adenoviral trans-
duction does not result in integration into the host
genome25 and endothelial cells have a half-life mea-
sure in years,26 it is possible that the induction of tol-
erance may occur. CTL would fail to recognize and
lyse the adenoviral-transduced cell with limited
MHC-I expression and thus prolong the lifespan of
the adenoviral-infected cell.
In summary, these results show that the trans-
duction of vascular endothelial and smooth muscle
cells and dermal fibroblasts with AdICP47 results in
a significant specific reduction in both constitutive
and γ-IFN–induced MHC-I on the major cell con-
stituents of the vascular wall. Furthermore,
AdICP47-transduced endothelial cells exhibited a
substantial reduction in cytolysis by CTL, which is
specific for MHC-I molecules on the cell surface.
The extent of AdICP47-induced MHC-I inhibition
and its impact on acute vascular rejection remains to
be established in an appropriate in vivo model.
Table I. Effect of AdICP47 on endothelial cell
VCAM/ICAM expression
Constitutive mean TNF-induction mean
VCAM
Nontransduced 3.99 239.00
AddlE1 6.00* 138.59*
AdICP47 5.73* 150.76*
ICAM
Nontransduced 12.35 2169.67
Add1E1 158.40* 1640.27
AdICP47 173.20* 3073.30†
*P < .05 versus nontransduced.
†P < .05 versus AddlE1.
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